Dermex Dermex II
Executive Summary
Dermatologic committee will discuss NDA 20-996 for Dermex Pharmaceuticals' zinc oxinate ointment for treatment of actinic keratosis, basal cell carcinoma and squamous cell carcinoma at its June 29 meeting. The committee will also discuss Schering-Plough's NDA for Lotrisone the same day (1"The Pink Sheet" May 29, In Brief). The meeting will be at the Holiday Inn in Bethesda, Md. at 10 a.m. The committee review of J&J's miconazole nitrate will be on June 30 at 8:30 a.m
You may also be interested in...
Schering-Plough Lotrisone
FDA Dermatologic & Ophthalmic Drugs Advisory Committee will meet June 29 to discuss NDA 20-010 for Lotrisone lotion (clotrimazole/betamethasone) for the treatment of tinea pedis, tinea cruris and tinea corporis
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials